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Glucocorticoid receptor (GR) function may have aetiopathogenic signiﬁcance in chronic fatigue syndrome (CFS), via its essential
role in mediating inﬂammatory responses as well as in hypothalamic-pituitary-adrenal axis regulation. GR function can be
estimated ex vivo by measuring dexamethasone (dex) modulation of cytokine response to lipopolysaccharide (LPS), and in vivo
using the impact of dex on cortisol levels. This study aimed to compare the GR function between CFS (n = 48), primary
Sjögren’s syndrome (a disease group control) (n = 27), and sedentary healthy controls (HCs) (n = 20), and to investigate its
relationship with clinical measures. In the GR ex vivo response assay, whole blood was diluted and incubated with LPS
(to stimulate cytokine production), with or without 10 or 100 nanomolar concentrations of dex. Cytometric bead array (CBA)
and ﬂow cytometry enabled quantiﬁcation of cytokine levels (TNFα, interleukin- (IL-) 6, and IL-10) in the supernatants.
In the in vivo response assay, ﬁve plasma samples were taken for determination of total cortisol concentration using
ELISA at half-hourly intervals on two consecutive mornings separated by ingestion of 0.5mg of dex at 11 pm. The association of
the data from the in vivo and ex vivo analyses with reported childhood adversity was also examined. CFS patients had reduced
LPS-induced IL-6 and TNFα production compared to both control groups and reduced suppression of TNFα by the higher dose
of dex compared to HCs. Cortisol levels, before or after dex, did not diﬀer between CFS and HCs. Cortisol levels were more
variable in CFS than HCs. In the combined group (CFS plus HC), cortisol concentrations positively and ex vivo GR function
(determined by dex-mediated suppression of IL-10) negatively correlated with childhood adversity score. The results do not
support the hypothesis that GR dysregulation is aetiopathogenic in CFS and suggest that current and future endocrine
cross-sectional studies in CFS may be vulnerable to the confounding inﬂuence of childhood trauma which is likely increased by
comorbid depression.
1. Introduction
Chronic fatigue syndrome (CFS) has a prevalence of 2% in
the UK [1, 2]. It is deﬁned by profound, persistent, medically
unexplained fatigue lasting at least 6 months, which is not
caused by ongoing exertion, not signiﬁcantly eased by rest,
and is severe enough to cause considerable loss of function
[3–5]. Alongside this are symptoms of inﬂammation, pain,
cognitive deﬁcits, and psychiatric and bowel problems [4].
Often, biological tests and physical examinations are unre-
markable. CFS aﬀects all ages and the peak age of onset is
20–40. Full recovery is rare [2, 6] and comorbidity with
depression is common.
Many putative causes of CFS have been investigated
but the absence of an agreed pathogenesis impacts the
development of eﬀective diagnostics and treatments. It is
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likely thatmultiple factors contribute which involve a number
of interacting biological, environmental, and psychosocial
factors [1, 2, 5, 7–11].
The recognised temporal relationship between stressors
and the onset and course of CFS suggests an aetiopathogenic
role for systems controlling the stress response including the
sympathetic nervous system and the hypothalamic-pituitary-
adrenal (HPA) axis [4, 8, 12–17]. The functionality of the
glucocorticoid receptor (GR), determined by its sensitivity,
aﬃnity, and density and by its interaction with transcription
factors [18], is arguably the deﬁning factor in HPA axis
regulation [19] and responsible, in a large part, for basal
concentrations of cortisol throughout the day. In HPA axis
downregulation in response to the GR agonist, dexametha-
sone (dex) is the most commonly used in vivo method of
determining GR function. An ex vivo technique dependent
on the inhibitory eﬀect of GR activation on cytokine
release is also utilized [20, 21]. Cross-sectional studies in
CFS tend to show basal hypocortisolaemia [22, 23], atten-
uated diurnal variation [4, 24], an attenuated response to
activation by CRH or ACTH [16, 23, 25–28], an enhanced
suppression by dex [10, 17, 28–30], and an enhanced dex-
induced suppression of IL-6, TNFα, IL-10, and IL-4 syn-
thesis [21, 31, 32] and of peripheral blood mononuclear
cell proliferation [18]. Genetic studies in CFS have shown
the salience of functional single nuclear polymorphisms in
NR3C1 [31, 32], which codes for GR, and have also shown
hypomethylation of the 1F promotor region of this gene
[33–35]. The endocrine ﬁndings however are not consis-
tent, and elevated [36] or normal [18, 27, 25, 37] basal
cortisol levels have also been reported, as has a normal
cortisol response to wakening [25] and to psychosocial
stress [21, 38]. There is also some evidence of an associa-
tion of HPA axis dysregulation with symptom severity and
poorer prognosis [15, 39] but only speculation about the
mechanism through which HPA axis abnormalities may
result in the symptoms of CFS; glucose supply [40], hypo-
tension with associated reduced cerebral perfusion [41],
and CRH-induced appetite and sleep disturbance have
been considered [16].
The HPA axis interacts with many other systems, notably
the immune system [42]. Glucocorticoids (GCs) modulate
immune responses by altering gene expression, transcription,
translation, and protein secretion [42], either directly, by
decreasing transcription of the genes which code for cyto-
kines, or indirectly, by inhibiting proinﬂammatory transcrip-
tion factors [42]. GCs inhibit, with diﬀerent sensitivities,
cytokines such as IL-6, IL-1, and TNF (TNF the most, IL-6
the least) [42, 43]. Immune activation, with an increase in
proinﬂammatory cytokine concentrations, including IL-6,
TNFα, and IL-1 [2, 44, 45], has been rather inconsistently,
for example [32], demonstrated in CFS, may be secondary
to insuﬃcient glucocorticoid signaling [7], and may result
in pain, fatigue, cognitive deﬁcits, and other symptoms which
are characteristic of CFS [12, 16, 38, 46].
In order to examine the nature, extent, and impact of
HPA axis dysregulation in CFS, we sought to compare GR
function using both in vivo and ex vivo assessment. We
therefore examined the HPA axis and immune system
function in a sample of patients with CFS and in healthy
comparators and in participants with the systemic autoim-
mune condition, primary Sjögren’s syndrome (pSS), who
acted as disease group comparators.
2. Methods
2.1. Participants. Three groups were recruited. The study was
carried out in accordance with the Declaration of Helsinki.
The study design was approved by the Newcastle and North
Tyneside Ethics Committee. All participants provided writ-
ten informed consent. Participants were aged 22–68 years
old. Exclusion criteria consisted of age< 18 years, a current
or past axis I psychiatric diagnosis conﬁrmed using the Struc-
tured Clinical Interview for DSM-IV [47, 48], and use, in the
72 hours prior to enrolment, of antihypertensives, antide-
pressants, or analgesics. Samples were collected as part of
an MRC-funded cohort study (MRCMR/J002712/1). 48 par-
ticipants with CFS (13 males (mean age 52.2) and 35 females
(mean age=44.9)) were recruited via the local CFS clinical
service, all fulﬁlled the Fukuda diagnostic criteria, and had
a mean FIS of 88 and CTQ of 32. Twenty healthy compara-
tors (HC; 7 males (mean age= 43.1) and 13 females (mean
age 44.9)) were recruited from a HC database, word of
mouth, social media, and advertisement in the hospital
(mean FIS= 4, CTQ=29). HCs were age and sex matched
to the patients, and attempts were made to match on activity
levels using the Mean International Physical Activity Ques-
tionnaire (IPAQ) although the mean CFS IPAQ rating was
“low” and the HC rating was “medium.” Primary Sjögren’s
syndrome (pSS) patients (n = 27) fulﬁlled the American
European Consensus Group classiﬁcation [49] and were
recruited from the United Kingdom pSS Registry [50].
2.2. Symptom Assessment Tools. The CFS participants com-
pleted the Fatigue Impact Scale (FIS) [51] and the Childhood
Trauma Questionnaire-Short Form (CTQ-SF) [52]. The FIS
quantiﬁes individual perception of the impact that fatigue
has on daily functioning (Fisk et al.) [53]. There are 40 items,
each scored on a 5-point Likert scale providing a continuous
scale of 0–160. It comprises three subscales looking at the
impact that fatigue has on physical (10 items: motivation,
eﬀort, stamina, and coordination), psychosocial (20 items:
isolation, emotions, coping, and workload), and cognitive
(10 items: concentration, memory, and thinking) function-
ing. A higher score indicates greater fatigue. The CTQ is a
28 item self-report scale which measures the frequency
and severity of childhood adversity. It consists of ﬁve fac-
tors: emotional abuse, physical abuse, sexual abuse, emo-
tional neglect, and physical neglect, and possesses good
psychometric properties [52]. Items are scored on a Likert
scale, with responses ranging from 1 (“never true”) to 5
(“very often true”).
2.3. In Vivo Assessment of HPA Axis Function by
Measurement of Cortisol Levels in Response to Low-Dose dex
in CFS Compared to Healthy Controls. In the 48 CFS patients
and the ﬁrst 10 healthy controls (HCs), plasma samples were
taken in lithium-heparin vacutainers at 30-minute intervals
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between 10 am and noon on two consecutive days (day 1 and
day 2). At 11 pm on day 1, participants took oral dex
(0.5mg). Practical consideration meant that only the baseline
blood (10 amday 1 sample) were taken for the other 10 HCs.
Within one hour of collection, the blood was spun at 1600 g
for 10 minutes at room temperature. Aliquots of plasma were
extracted and stored at −80°C until analysis. Plasma cortisol
concentrations were quantiﬁed using 15 lot-matched cortisol
ELISA kits, supplied by Abcam and used according to the
manufacturer’s protocol. The lower limit of cortisol detection
was 2.44 ng/ml.
2.4. Ex VivoMeasurement of GR Function: The Glucocorticoid
Receptor Response Assay. The GR response assay [20] utilised
lithium-heparin-treated blood taken at 10 am on day 1. It was
set up in sterile 48-well plates within 3 hours of collection.
Blood was diluted 1/10 with room temperature RPMI 1640
containing penicillin-streptomycin and L-glutamine, mixed
thoroughly by inversion, and then incubated for 24 hours at
37°C in a humidiﬁed atmosphere of 95% air and 5% CO2.
There were four conditions, “null” (medium alone),
“LPS” in which 50μl of a 200μg/ml LPS solution was
added to the 400μl of diluted blood (to stimulate cytokine
production from cells), “dex10” in which 50μl of a 100
nanomolar (nM) dex solution was also added, and
“dex100” in which a tenfold stronger dex solution was
added. After incubation, the assay plates were spun in a
4°C centrifuge for 10 minutes at 1000RPM. 300μl superna-
tant samples were then harvested for each condition, trans-
ferred to 0.6ml microcentrifuge tubes, and stored at −20°C.
Cytokine concentrations (TNFα, IL-6, and IL-10) were
determined using Cytometric Bead Array (CBA) and ﬂow
cytometry according to the manufacturer’s instruction
(BD Bioscience). Percentage suppression on dex 10 nM
(% dex10) and on dex 100nM (% dex100) was calculated
using the following equation:
% cytokine suppression
= 100 − raw cytokine level on dex10 nM or on dex100 nMraw LPS‐stimulated cytokine level × 100
1
2.5. Baseline Cytokine Levels. Gel-based specimen tubes were
used to collect a further serum sample at 10 am on day 1 for
baseline measurement of a range of inﬂammatory markers.
These were spun within 3 hours at 1600RPM for 10 minutes
at room temperature. 2× 1ml of serum was extracted and
stored at −80°C until analysis which utilized the method
described above, that is, CBA and ﬂow cytometry. Two dif-
ferent dilutions of serum samples were required for the mea-
surement of diﬀerent cytokines; this was therefore conducted
in 2 batches for CFS (n = 45), HC (n = 19), and pSS (n = 9)
participants.
2.6. Data and Statistical Analysis. Statistical tests were carried
out using SPSS version 23 and the “R” statistical package.
Graphs were produced using GraphPad Prism version 5.01
and MATLAB. p values are two-tailed with signiﬁcance set
at p < 0 05.
Repeated measures ANOVA was conducted with time
(5) as within and group (2) as between factors to examine
cortisol concentrations on each of the two days. Area under
the curve (AUC) was also calculated using trapezoid integra-
tion, both for day 1 and day 2. Speciﬁcally, AUC with respect
to ground (AUCg), considered to be a measure of overall cor-
tisol output including baseline activity, and AUC increase
(AUCi), a putative measure of the sensitivity of GR to mod-
ulation, were calculated [54]. The diﬀerence between AUCg
on the 2 days was also calculated (delta AUCg). Shapiro-
Wilk and QQ plots (data not shown) revealed that even after
Box-Cox transformation, neither AUC nor cytokine data met
the assumptions required for ANOVA; thus, nonparametric
comparisons were used. Spearman correlations were con-
ducted to examine the relationship between childhood adver-
sity and endocrine parameters. All data, shown or not shown,
is available for scrutiny upon request.
3. Results
3.1. InVivoAssessment ofHPAAxis Function byMeasurement
of Cortisol Levels in Response to Low-Dose dex in CFS
Compared to Healthy Controls. There was a signiﬁcant eﬀect
of time on day one (F = 16 61, df = 4, 56, p < 0 0005) but not
on day two (F = 0 87, df = 4, 56, p = 0 418). No eﬀect of group
on either day (day one, F = 0 73, df = 1, 56, p = 0 398; day 2,
F = 0 79, df = 1, 56, p = 0 378) (see Figure 1). Cortisol AUCs
(g or i, day one, day two, or delta) did not diﬀer (p > 0 2).
3.2. Ex Vivo Assessment of HPA Axis Function: The
Glucocorticoid Receptor (GR) Response Assay. GR response
assay blood was not taken for two CFS patients. One HC
was removed due to an abnormally high null value and one
CFS patient removed due to not stimulating suﬃciently on
LPS. Analysis was therefore conducted on samples taken from
CFS (n = 40), HC (n = 19), and pSS (n = 27) participants.
In the null sample, pSS participants had higher IL-10
levels than the CFS or HC participants but there were no dif-
ferences between groups for IL-6 or TNFα. LPS induced a
robust cytokine response, and after LPS, group diﬀerences
were evident such that, for the positive cytokines IL-6 and
TNFα, pSS participants had higher levels than CFS partici-
pants, who had higher levels than HCs. For IL-10, the diﬀer-
ence was between pSS (higher) and HCs. Median cytokine
levels were, on the whole, lower in the dex 10nM samples
and invariably in the dex 100nM samples than the LPS alone
samples. Percentage suppression was greater for samples
incubated with dex 100nM than those incubated with dex
10 nM. Percentage suppression with dex 10 nM or dex
100 nM was not diﬀerent between the groups, except for a
greater suppression in the dex 100nM condition determined
using TNFα (see Table 1).
Individual AUC and cytokine values were visualized
using frequency density plots. Visual inspection suggested
greater variability in patients compared to HCs with some
patients showing less suppression (see Figure 2). In order to
investigate this, we performed post hoc t-tests of standard
deviations derived from Bayesian hierarchical models of
outcome measures under Gaussian (normal) priors. The
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advantage of this approach lies in its treatment of parameters
as sampling variables rather than population attributes which
allows us to formally compare modelled estimates of their
values. Signiﬁcance was assessed by comparing the 95%
credible intervals of the posterior distributions. Vague
priors were used for the mean and standard deviation,
and analysis was carried out using the BEST package in
the R statistical environment [55]. Results are displayed
in Table 1. There was no diﬀerence in standard deviation of
day 1 AUCg distributions. There was a signiﬁcant diﬀerence
in standard deviations for day 1 AUCi (p = 014), day 2
AUCg (p < 0005), and day 2 AUCi (p < 0005). There was
also a signiﬁcant diﬀerence in standard deviations of TNF
distributions (p = 001). The diﬀerence in IL-6 was marginal
(p = 054) though there was no signiﬁcant diﬀerence in
IL-10 distributions (p = 774).
3.3. The Relationship between Reported Adversity and HPA
Axis Function in CFS and Controls. Correlation coeﬃcients,
in CFS participants, reveal a negative relationship between
the CTQ score (and the emotional subscores) and cortisol
AUC but no signiﬁcant relationship with % suppression
(after incubation with 10 nm dex). In HCs, there was no sig-
niﬁcant relationship between CTQ scores and cortisol AUC,
but there was a positive relationship with percentage IL-6
suppression (see Table 2). In the combined sample, of CFS
and HC (see Table 3), the signiﬁcant correlations were
between the CTQ total score and AUCg (positive) and IL-
10 (negative).
3.4. Baseline Cytokine Levels. CFS patients showed reduced
production of IP-10 and IL-12/23p40 compared to HC and
of IP-10, MIP1α, IL-6, and IL-1β compared to pSS partici-
pants. pSS participants showed increased production of
MIP1α and IL-6 compared to HV. A violin plot was designed
post hoc using “R” statistical software to visualize variance
between populations and determine whether subpopulations
were present and is displayed in Figure 3.
4. Discussion
We did not demonstrate a diﬀerence in cortisol levels
between participants with CFS and healthy volunteers. This
diﬀers from the majority of cross-sectional HPA axis studies
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Figure 1: Total cortisol values at ﬁve time points over two days in participants with CFS and healthy controls. Bar chart showing cortisol
concentrations in CFS patients and healthy controls at ﬁve morning time points over two consecutive days. Participants administered oral
dex at 11 pm on day 1. Data are shown as mean plus standard error of the mean.
Table 1: Standard deviations for endocrine data between chronic fatigue and healthy participants.
CFS Healthy controls Diﬀerence p value
Day 1 AUCg 79.4 (63.1, 97.5) 72.1 (38.3, 113.2) 7.32 (−38.8, 48.4) 0.389
Day 1 AUCi 66.3 (52.9, 81.0) 27.5 (14.9, 43.4) 38.75 (16.9, 60.3) 0.014
Day 2 AUCg 25.4 (20.0, 31.4) 6.8 (3.7, 10.8) 18.61 (11.6, 25.8) <0.0005
Day 2 AUCi 16.1 (12.7, 19.7) 5.3 (2.8, 8.4) 10.75 (5.9, 15.5) <0.0005
% suppression TNFα 31.2 (24.3, 39.0) 15.6 (10.5, 21.3) 15.6 (6.1, 25.1) 0.001
% suppression IL-6 18.3 (14.2, 22.9) 13.0 (8.9, 17.9) 5.3 (−1.2, 11.8) 0.054
% suppression IL-10 47.4 (36.5, 59.3) 56.4 (38.2, 78.0) −9.1 (−33.8, 13.9) 0.774
AUCg: area under the curve with respect to ground; AUCi: area under the curve with respect to increase. The % suppressions refer to the percentage diﬀerence
in cytokine concentration in the dexamethasone 10 nM condition compared with the LPS condition. Values presented are the mean values of the posterior
distribution of standard deviations with 95% credible intervals in brackets. Diﬀerences are signiﬁcant if the credible interval does not include zero. p values
refer to the proportion of the posterior mean standard deviation diﬀerence plot which is less than or equal to zero.
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in this population (see “Introduction” and [10] for review).
This diﬀerence may be related to the population; the sample
here, for instance, was rigorously screened for comorbid
depression, and Papadopoulos et al. [36] have previously
demonstrated that dex-induced cortisol suppression diﬀered
only in CFS patients with comorbid depression or it may be a
type II error consequent on the small sample size combined
with the marked variation in cortisol levels in CFS as
highlighted by the frequency density graph and the signiﬁ-
cantly greater cortisol variability in patients with CFS. The
aetiopathogenic relevance of this variability is unknown but
it suggests a lack of precision in cortisol regulation [56].
The heterogeneity in cortisol concentrations may suggest
clinical heterogeneity within the diagnostic grouping of CFS
and emphasizes the impact of disparate and competing fac-
tors on GR function including current and previous stressors,
the common use of antidepressants [20, 54] (even in those
who have never met criteria for major depressive disorder)
[20, 57], and the impact of a primary dysregulation of proin-
ﬂammatory cytokines [58].
The baseline cytokine data emphasized the status of pSS
as an inﬂammatory disorder. The ex vivo data revealed a
reduced capacity for a proinﬂammatory cytokine response
to LPS in CFS compared with HCs (and an increased respon-
sivity compared to the pSS participants). It further revealed
that (independent of group) incubation with dex, in a dose-
dependent manner, as expected, suppressed cytokine release.
The percent suppression of LPS-induced TNFα release by
100 nM solution of dex was less in CFS patients than HCs.
This may be suggestive of reduced GR function in CFS but
any such interpretation must be made with caution as the
impact of 10nM dex did not signiﬁcantly diﬀer between
CFS and HCs, neither was a signiﬁcant eﬀect seen when
IL-6 or IL-10 was used as the output variable. That TNFα
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6 Mediators of Inﬂammation
was most sensitive to suppression by dex accords with the
existing literature [42], is congruent with the theory that
GCs may preferentially inhibit Th1 over Th2 cells [59], and
suggests that TNFα may be the most appropriate cytokine
for GR response assay studies in CFS. The variability in per-
centage suppression of cytokine levels by dex is also greater in
CFS than healthy or pSS controls.
In CFS participants, there was a relationship between the
score on the childhood trauma questionnaire and cortisol
AUCs such that higher reported levels of early adversity
correlated negatively with cortisol. Interestingly, a diﬀerent
pattern was seen in healthy volunteers in whom reported
childhood adversity associated positively with dex-induced
IL-6 suppression in the absence of an eﬀect of cortisol con-
centrations. When the groups were combined to maximise
power, a negative relationship between reported adversity
and cortisol levels and a positive relationship with GR func-
tion (here shown using IL-10 not IL-6) are revealed.
The variability in cortisol has implications for the inter-
pretation of existing and future endocrine cohort studies in
CFS because of the associated risk of type I and type II
errors; our data, for instance, would suggest that the pro-
portion of participants in a sample who experienced child-
hood adversity will be expected to determine the
likelihood that basal hypocortisolaemia will be shown. In
addition to the CTQ total score, we report here also the
emotional neglect subscale, having previously argued that
the pervasive nature of emotional neglect ensures that it
enacts the greater sustained impact on behavioural and
endocrine function [60, 61].
There can be few who argue with the notion that, in
the general population, early adversity, acting for instance
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8 Mediators of Inﬂammation
through methylation or other epigenetic mechanisms,
impacts GR function and so GR mediated negative feedback
on the HPA axis and thus cortisol synthesis [62, 63] and,
further, that this has relevance for understanding the patho-
physiology of mood disorders [64]. It is of interest, here, to
consider the implication that this has for our understanding
of the pathophysiology of CFS and for the interpretation of
endocrine studies in this population. We have previously
postulated that childhood adversity is not a risk factor for
CFS per se, but it can appear to be because of the impact of
comorbid or misdiagnosed depression [65]. It has been
further conjectured that comorbid depression may com-
monly confound CFS studies [36] and, just as this may
lead to erroneous ﬁnding of increased rates of childhood
adversity in CFS, similarly, it may explain the methylation
pattern [66] including in the NR3C1-1F promoter region
[33], the increased GR function (shown using the DST,
the dex/CRH test [28], or ex vivo measures), and the basal
hypocortisolaemia which have been (inconsistently [10])
shown in previous CFS studies. In this current study,
CTQ scores were not greater in the CFS participants than
HCs, and it is interesting to note that the basal cortisol or
GR function as determined by post-dex cortisol or dex-
induced suppression of cytokine synthesis was not con-
vincingly diﬀerent.
Despite our rigorous exclusion of those who met the
diagnostic criteria for depression and the lack of diﬀerence
in childhood adversity reported by CFS patients compared
with HCs, there was a signal that HPA axis regulation was
diﬀerent in CFS; the variability of pre- and post-dex corti-
sol levels and of dex-induced cytokine suppression was
increased in CFS, the proinﬂammatory cytokine response
to LPS was attenuated, and the TNFα suppression by the
larger dex dose was greater, and, whilst we do not want
to make too much of this, the graph suggested (but the
stats did not back up) the possibility that post-dex cortisol
was lower in CFS than HCs. Further research is needed to
understand the cause and signiﬁcance of this data; this will
need large, well-characterised groups and will need consid-
eration to be given to the interacting networks of biologi-
cal, psychological, and social factors.
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